NuCana PLC
Change company Symbol lookup
Select an option...
NCNA NuCana PLC
TSM Taiwan Semiconductor Manufacturing Co Ltd
SCRH Scores Holding Company Inc
CB Chubb Ltd
RICK RCI Hospitality Holdings Inc
NAK Northern Dynasty Minerals Ltd
SFUN Fang Holdings Ltd
IFF International Flavors & Fragrances Inc
POL PolyOne Corp
KWR Quaker Chemical Corp
Go

Health Care : Biotechnology |
Based in United KingdomCompany profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.

Closing Price
$11.94
Day's Change
0.29 (2.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
12.79
Day's Low
11.73
Volume
(Light)
Volume:
4,095

10-day average volume:
66,128
4,095

Netflix shares down 2% premarket as SunTrust slashes stock price target

7:39 am ET January 2, 2019 (MarketWatch)
Print

Netflix Inc. shares (NFLX) slid 2% in premarket trade Wednesday, after SunTrust Robinson Humphrey slashed its stock price target to $355 from $410 and said it expects fourth-quarter subscriber additions to be slightly below consensus and the company's own guidance. Analysts led by Matthew Thornton said content released in December, including a Taylor Swift concert, the film "Bird Box" starring Sandra Bullock and a film length "Black Mirror' episode should close the gap. "But meaningful 4Q upside looks unlikely. We're updating our model (recent debt raise; 2019 quarterlies) and lowering our price target to $355 (higher rates, lower comp multiples) based on DCF (discounted cash flow)," they wrote in a note. SunTrust is sticking with its buy rating on the stock, however, as it expects an improved content slate heading into mid-year. Reports that the company is about to hire a new CFO--Spencer Neumann from Activision Blizzard Inc. (ATVI)--would also be a positive, if true, said the note. Shares have gained 33% in the last 12 months, while the S&P 500 has fallen 7%.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

January 02, 2019 07:39 ET (12:39 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.